OBJECTIVES Apolipoprotein E gene (APOE) polymorphism is associated with the lipid profile and cardio-vascular disease. However, these relationships vary between ethnic groups. We evaluated, for the first time in an Afro-Caribbean population, the distribution of APOE polymorphisms and their associations with coronary artery disease (CAD), the lipid profile and other cardio-metabolic risk factors...

The apolipoprotein E (APOE) gene may act differently in young and old persons, known as antagonistic pleiotropy. We therefore examined the prospective associations between the APOE ε4 allele and cognitive functioning, and the modifying effect of age, in 375 nondemented adults (mean age 57 ± 10 years; follow-up period 3.8 ± 0.2 years) with available data on APOE genotype and cognitive functionin...

This study was designed to explore the influence of apolipoprotein E (APOE) on blood phospholipids (PL) in predicting preclinical Alzheimer's disease (AD). Lipidomic analyses were also performed on blood from an AD mouse model expressing human APOE isoforms (EFAD) and five AD mutations and from 195 cognitively normal participants, 23 of who converted to mild cognitive impairment (MCI)/AD within...

Alzheimer's disease (AD) is the most common progressive neurodegenerative disorder causing dementia. Massive deposition of amyloid β peptide (Aβ) as senile plaques in the brain is the pathological hallmark of AD, but oligomeric, soluble forms of Aβ have been implicated as the synaptotoxic component. The apolipoprotein E ε 4 (apoE ε4) allele is known to be a genetic risk factor for developing AD...

The apolipoprotein E (APOE) ε4 allele constitutes the major genetic risk for the development of late onset Alzheimer's disease (AD). However, its influence on the neurodegeneration that occurs in early AD remains unresolved. In this study, the resting state magnetoencephalography(MEG) recordings were obtained from 27 aged healthy controls and 36 mild cognitive impairment (MCI) patients. All par...

Alzheimer’s disease (AD) is a chronic neurodegenerative disease and the most common cause of dementia. AD risk is foremost modified by allelic composition of the APOE gene encoding apolipoprotein (apo) E-brain’s main lipid carrying protein. Emerging evidence suggests that APOE genotype also may modulate efficacy and safety of AD immunotherapy, which is under development as a potential disease-m...

BACKGROUND The ε4 allele of the Apolipoprotein E gene (APOE-ε4) is a potent genetic risk factor for sporadic Alzheimer's disease (AD). Amnestic mild cognitive impairment (aMCI) is an intermediate state between normal cognitive aging and dementia, which is easy to convert to AD dementia. It is an urgent problem in the field of cognitive neuroscience to reveal the conversion of aMCI-ε4 to AD. Bas...

Background The APOE (allele ε4) and PICALM (SNPs rs541458: allele T; rs3851179: G) genes were recognized as risk factors for late-onset Alzheimer’s disease (AD). However, effects of these on the cognitive functions healthy individuals are still not determined their possible interactions have never been studied. We investigated preclinical influence both brain in a middle-aged population. Method...

Alzheimer's disease (AD) is the most common cause of dementia among the elderly and accounts for 50-70% of all the demented cases. The major AD hallmark lesions are senile/neuritic plaques (SP/NP) and neurofibrillary tangles (NFT). The ApoE ε4 genotype is one of the riskfactors for AD. The present study showed that the prevalence of the ApoE ε4 genotype was higher among AD cases and the number ...

BACKGROUND Several studies have demonstrated a lower apolipoprotein E4 (APOE ε4) allele frequency in African-Americans, but yet an increased age-related prevalence of AD. An algorithm for prevention clinical trials incorporating TOMM40'523 (Translocase of Outer Mitochondria Membrane) and APOE depends on accurate TOMM40'523-APOE haplotypes. METHODS We have compared the APOE and TOMM40'523 phas...